Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy
Status:
RECRUITING
Trial end date:
2026-07-20
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and toxicity of sodium glycididazole combined with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy.
Phase:
PHASE2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences